NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.) インテリア・セラピュ―ティクス

 NTLAのチャート


 NTLAの企業情報

symbol NTLA
会社名 Intellia Therapeutics Inc (インテリア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インテリア・セラピューティクス(Intellia Therapeutics Inc.)はゲノム編集会社である。同社はCRISPR/Cas9という生物学的ツールを利用した治療法の開発に従事する。CRISPR/Cas9ゲノム編集システムは2つの成分を含む。Cas9タンパク質は遺伝子のノックアウト・修復・挿入のための自然細胞修復プロセスを開始する分子ハサミのように働く。ガイドRNA配列はCas9を特定の標的デオキシリボ核酸(DNA)配列に認識し導く。同社のセンチネルインビボプログラムは、肝臓へのCRISPR/Cas9複合体の送達のための脂質ナノ粒子(LNP)の使用に焦点を当てる。同社の事業部であるeXtellia Therapeuticsは、免疫腫瘍学・自己免疫性疾患・炎症性疾患の分野におけるCRISPR / Cas9ゲノム編集の応用に従事する。同社の子会社はIntellia Securities Corpを含む。   インテリア・セラピュ―ティクスは米国のライフサイエンス企業。遺伝子改変技術に取り組み、ゲノム編集ツ―ルである「クリスパ―・キャス9(CRISPR/Cas9)」システムを利用し、トランスチレチン・アミロイド症やB型肝炎、アンチトリプシン欠乏症などの治療を可能にする。本社はマサチュ―セッツ州ケンブリッジ。   Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
本社所在地 40 Erie Street Suite 130 Cambridge MA 02139 USA
代表者氏名 Perry A. Karsen ペリーA.カーセン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-285-6200
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 195人
url www.intelliatx.com
nasdaq_url https://www.nasdaq.com/symbol/ntla
adr_tso
EBITDA EBITDA(百万ドル) -82.90700
終値(lastsale) 24.21
時価総額(marketcap) 1045887324.93
時価総額 時価総額(百万ドル) 958.62210
売上高 売上高(百万ドル) 29.13100
企業価値(EV) 企業価値(EV)(百万ドル) 653.08410
当期純利益 当期純利益(百万ドル) -82.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intellia Therapeutics Inc revenues increased 25% to $15.1M. Net loss increased 54% to $43.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 58% to $40.9M (expense) Stock-based Compensation in R&D increase of 64% to $5M (expense).

 NTLAのテクニカル分析


 NTLAのニュース

   Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down to $24.81  2020/10/24 22:30:42 Daily Political
Intellia Therapeutics Inc (NASDAQ:NTLA)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $24.81, but opened at $22.50. Intellia Therapeutics shares last traded at $22.50, with a volume of 38 shares traded. Several equities research analysts have commented on NTLA shares. Goldman Sachs Group started coverage on […]
   Navidea Biopharmaceuticals (NYSE:NAVB) and Intellia Therapeutics (NYSE:NTLA) Head-To-Head Contrast  2020/10/24 08:00:51 Dakota Financial News
Navidea Biopharmaceuticals (NYSE:NAVB) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation. Analyst Recommendations This is a summary of recent ratings and recommmendations for Navidea Biopharmaceuticals and […]
   Intellia Therapeutics (NASDAQ:NTLA) Trading Up 5.6%  2020/10/22 19:36:59 US Banking News
Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price was up 5.6% during trading on Thursday . The company traded as high as $24.89 and last traded at $24.81. Approximately 591,227 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 858,636 shares. The stock had previously closed at $23.49. A number […]
   Intellia Therapeutics (NASDAQ:NTLA) Shares Down 5.5%  2020/10/22 10:00:06 Stock Observer
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 5.5% during trading on Tuesday . The stock traded as low as $24.11 and last traded at $24.35. 717,427 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 857,311 shares. The stock had previously closed at $25.77. Several analysts recently […]
   Roth Capital Raises Intellia Therapeutics (NASDAQ:NTLA) Price Target to $26.00  2020/10/22 09:30:42 Transcript Daily
Intellia Therapeutics (NASDAQ:NTLA) had its target price boosted by Roth Capital from $16.00 to $26.00 in a research note issued to investors on Monday, The Fly reports. Roth Capital currently has a neutral rating on the stock. NTLA has been the topic of a number of other reports. Wells Fargo & Company began coverage on […]
   Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/03 12:00:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing…
   GEMoaB et Intellia Therapeutics concluent un accord de collaboration de recherche et d'octroi de licence concernant l'immunothérapie cellulaire nouvelle génération basée sur les plateformes propriétaires de modification localisée de séquence génomique RevCAR et CRISPR/Cas9  2020/07/21 04:26:00 PR Newswire
- GEMoaB et Intellia vont allier technologies exclusives et expertise en recherche et développement afin de créer des immunothérapies cellulaires allogènes transformatrices contre des cibles prometteuses dans des maladies oncologiques et inflammatoires - GEMoaB recevra des paiements…
   Intellia Therapeutics partners with GEMoaB to develop immunotherapies (NASDAQ:NTLA)  2020/07/20 12:54:00 Seeking Alpha
Intellia (NASDAQ:NTLA) announces a research collaboration with privately held GEMoaB, wherein the companies will combine GEMoaB's proprietary RevCAR techno
   GEMoaB und Intellia Therapeutics beschließen Forschungszusammenarbeit und Lizenzvereinbarung über zelluläre Immuntherapien der nächsten Generation auf Grundlage der patentrechtlich geschützten Technologie-Plattformen RevCAR und CRISPR/Cas9  2020/07/20 12:00:00 PR Newswire
GEMoaB und Intellia planen, ihre patentrechtlich geschützten Technologien und Forschungs- und Entwicklungsexpertise zu kombinieren, um bahnbrechende allogene zelluläre Immuntherapien für schwer behandelbare Erkrankungen in der Onkologie und bei Immunologischen Erkrankungen zu entwickeln…
   GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms  2020/07/20 12:00:00 PR Newswire
DRESDEN, Germany, July 20, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, announced today that it has entered into a research collaboration and license agreement with Intellia (Nasdaq:…
   GEMoaB et Intellia Therapeutics concluent un accord de collaboration de recherche et d'octroi de licence concernant l'immunothérapie cellulaire nouvelle génération basée sur les plateformes propriétaires de modification localisée de séquence génomique RevCAR et CRISPR/Cas9  2020/07/21 04:26:00 PR Newswire
- GEMoaB et Intellia vont allier technologies exclusives et expertise en recherche et développement afin de créer des immunothérapies cellulaires allogènes transformatrices contre des cibles prometteuses dans des maladies oncologiques et inflammatoires - GEMoaB recevra des paiements…
   Intellia Therapeutics partners with GEMoaB to develop immunotherapies (NASDAQ:NTLA)  2020/07/20 12:54:00 Seeking Alpha
Intellia (NASDAQ:NTLA) announces a research collaboration with privately held GEMoaB, wherein the companies will combine GEMoaB's proprietary RevCAR techno
   GEMoaB und Intellia Therapeutics beschließen Forschungszusammenarbeit und Lizenzvereinbarung über zelluläre Immuntherapien der nächsten Generation auf Grundlage der patentrechtlich geschützten Technologie-Plattformen RevCAR und CRISPR/Cas9  2020/07/20 12:00:00 PR Newswire
GEMoaB und Intellia planen, ihre patentrechtlich geschützten Technologien und Forschungs- und Entwicklungsexpertise zu kombinieren, um bahnbrechende allogene zelluläre Immuntherapien für schwer behandelbare Erkrankungen in der Onkologie und bei Immunologischen Erkrankungen zu entwickeln…
   GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms  2020/07/20 12:00:00 PR Newswire
DRESDEN, Germany, July 20, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, announced today that it has entered into a research collaboration and license agreement with Intellia (Nasdaq:…
   The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs  2020/07/10 11:25:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (NASDAQ: NEO ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Penumbra Inc (NYSE: PEN ) Qiagen NV ( NYSE: QGEN ) Quidel Corporation (NASDAQ: QDEL ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) TG Therapeutics Inc (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 9) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Evolus Inc (NASDAQ: EOLS ) immatics biotechnologies GmbH (NASDAQ: IMTX ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Polypid Ltd (NASDAQ: PYPD ) Recro Pharma Inc (NASDAQ: REPH ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Ziopharm Announces Initiation of Phase 1 Trial For Blood Cancer Cell Therapy ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) said it has initiated a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, or …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インテリア・セラピュ―ティクス NTLA Intellia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)